Skip to main content
MEDS
NASDAQ Trade & Services

DataMeds AI Reports Q2 Revenue Beat, $18.4M Loss, and $6.5M Funding

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Neutral
Importance info
7
Price
$1.5
Mkt Cap
$4.207M
52W Low
$1.255
52W High
$97.5
52W Position info
20% above low
Off High info
98% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

MEDS sits 20% above its 52-week low of $1.255.

Summary

DataMeds AI reported Q2 revenue of $1.779M, up 14% sequentially, but a net operating loss of $18.4M. The company raised $6.5M in new funding and restructured $14.5M of debt, while lock-up agreements cover ~49% of shares outstanding.


Key Events · Earnings and Guidance · MEDS

  • Q2 Revenue Beat

    Revenue grew 14% sequentially to $1.779M, exceeding management projections, but gross profit was only $182K.

  • Large Operating Loss

    Net operating loss of $18.4M in Q2 2026, driven by an $8.9M loss on extinguishment of debt and higher G&A expenses.

  • New Funding and Debt Restructuring

    Raised $6.5M in June 2026 and restructured $14.5M of pre-existing debt to provide a path to preferred equity swap.

  • Lock-Up Agreements

    Holders of 1,533,930 common shares (~49% of shares outstanding) entered into lock-up agreements for at least 90 days.


Analysis · MEDS · Trade & Services

DataMeds AI's Q2 revenue grew 14% sequentially to $1.779M, beating management projections, but the company still posted a net operating loss of $18.4M, largely due to an $8.9M loss on debt extinguishment. The company raised $6.5M in June and restructured $14.5M of debt, providing runway for its turnaround. The upcoming Health Lives Here app launch with NFL Alumni Health in September is a key milestone, and lock-up agreements covering ~49% of shares outstanding reduce near-term selling pressure. However, the company remains in a precarious financial position with a stockholders' deficit of $19.5M and ongoing Nasdaq delisting risk.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MEDS was trading at $1.50 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.26 to $97.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MEDS - Latest Insights

MEDS
Nov 16, 2026, 8:42 AM EST
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.7001
Real-time Price: $0.6232 info
Change: -$0.0769 (-11%) info
Market Cap: $2.884M info
MEDS
Nov 16, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $0.6232 info
Change: -$0.0868 (-12%) info
Market Cap: $2.884M info
MEDS
Nov 13, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7251
Real-time Price: $0.6232 info
Change: -$0.1019 (-14%) info
Market Cap: $2.884M info
MEDS
Nov 13, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7499
Real-time Price: $0.6232 info
Change: -$0.1267 (-17%) info
Market Cap: $2.884M info
MEDS
Nov 13, 2026, 10:20 AM EST
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.8795
Real-time Price: $0.6232 info
Change: -$0.2563 (-29%) info
Market Cap: $2.884M info